OIPE SEP 0 9 2004 JC103 PATENT & TRADEMARK OFFICE
OIPE SEP 0 9 2004 JC103 PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John P. FORD

Serial No. 10/684,203

Filing Date: October 10, 2003

For: TREATMENT, COMPOSITIONS AND METHOD BASED ON URACIL COMPOUND

Docket No.: 41421.0101 CIP1 (new)

Group Art Unit: 1614

Examiner: Dwayne C. Jones

Customer No. 25213

EXPRESS MAIL LABEL NO. EL 976 544 157 US
Date Mailed: September 9, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication, except U.S. patents and patent application publications (1276 OG 55), is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §§ 1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

09/15/2004 MMEKONEN 00000100 081641 10684203
01 FC:1806 180.00 DA

☐ This statement qualifies under *37 C.F.R. §1.97*, subsection (b) because (check all that apply):

☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)

-- OR --

☐ (2) It is being filed within 3 months of entry of a national stage

-- OR --

☐ (3) It is being filed before the mail date of the first Office Action on the merits

-- OR --

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ *37 C.F.R. §1.97(c)*. If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; **or**

☒ a fee of $180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ *37 C.F.R. §1.97(d)*. If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of $130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization*. The Commissioner is hereby authorized to charge the above-referenced fees of $180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 41421-0101 CIP1).

Respectfully submitted,

Date: 9 SEPT 2004

By: 

Daniel M. Becker (Reg. No. 38,376)

HELLER EHRMAN WHITE & McAULIFFE LLP
Customer No. 25213

OIPE
SEP 09 2004
PATENT & TRADEMARK OFFICE

Form PTO-1449	Attorney's Docket No. 41421.0101 CIP1	Application Serial No. 10/684,203
INFORMATION DISCLOSURE STATEMENT	Applicant(s) John P. FORD	
(use several sheets if necessary)	Filing Date: October 10, 2003	Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1						
	2						
	3						
	4						
	5						

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
	6							
	7							
	8							

OTHER DOCUMENTS
(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	9	Chua D. et al., Proc Am Soc Clin Oncol 22. "Efficacy of capecitabine monotherapy in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy," p. 511, 2003.
	10	Childress J. et al., American Journal of Clinical Oncology, Vol. 26, No. 5. "Cutaneous Hand and Foot Toxicity Associated with Cancer Chemotherapy," pp. 435-436, Oct. 2003
	11	Powis, G., International Encyclopedia of Pharmacology and Therapeutics, Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents," pp 42-50, 1994
	12	Elasmar, et al., Jpn J Clin Oncol 2001; 31(4)172-174. "Case Report: Hand-Foot Syndrome Induced by Oral Fluoropyrimidine S-1
	13	Ehrlanger M. et al., Dermatologica 140, Suppl. I. "Cutaneous Absorption and Urinary Excretion of 6-14C-5-Fluorouracil Ointment Applicated in an Ointment to Healthy and Diseased Human Skin," pp. 129-136, 1970.
	14	Fischel J-L., et al., Proceedings of the American Association for Cancer Research, Vol. 45. "Experimental arguments for a better understanding of hand-foot syndrome under capecitabine," p. 487, March 2004.
	15	Findlay M. et al., Annals of Oncology 7:47-53. "Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients in protracted venous infusion with or without interferon-α," pp. 111-117, 1996
	16	Fujii S. et al., Gann, 70. "Effect of Coadministration of Uracil or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents," pp. 209-214, April, 1979
	17	Fukushima S, et al., Cancer Research 52. "Carcinogenicity of Uracil, a Nongenotoxic Chemical, in Rats and Mice and I Rationale," pp. 188-193, April 1, 1992
	18	Gallo R, et al., The Journal of Clinical Investigation, Vol. 48, "The Enzymatic Mechanisms for Deoxythymidine Synthesis in Human Leukocites," pp. 82-93, 1969
	19	Hatfield D., et al., The Journal of Biological Chemistry. "Synthesis of (3-Ribosyluric Acid) 5'-Phosphate and (3-Ribosylxanthine) 5'-Phosphate by a Pyrimidine Ribonucleotide Pyrophosphorylase of Beef Erythrocytes," pp. 60-66, August 1964

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

Form PTO-1449	Attorney's Docket No. 41421.0101 CIP1	Application Serial No. 10/684,203
INFORMATION DISCLOSURE STATEMENT	Applicant(s) John P. FORD	
(use several sheets if necessary)	Filing Date: October 10, 2003	Group Art Unit: 1614

OTHER DOCUMENTS
(including author, title, date, pertinent pages, etc.)

	20	Paulo Hoff, Investigational New Drugs 18. "The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL™) and S-1:a review of their clinical development and therapeutic potential," pp. 153-163, 2000
	21	Ichikawa W., et al., British Journal of Cancer (2003) 89. "Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer," 2003 Cancer Research UK
	22	Ikenaka K., et al., Gann, 70. "Effect of Uracil on Metabolism of 5-Fluorouracil *in Vitro*," pp. 353-359, June, 1979
	23	Johnson M., et al., Clinical Cancer Research, Vol. 5. "Life-Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-Deficient Patient after Treatment with Topical 5-Fluorouracil," pp. 141-146, August 1999
	24	Kawaguchi Y., et al., Gann, 71. "Studies on the Metabolism of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Uracil Co-Administered Orally to Tumor-Bearing Rats," pp. 889-899, December, 1980
	25	Largillier R., et al., General Poster Session. "Prospective Analysis of Dihydropyrimidine Dehydrogenase (Dpd) Activity for Predicting Capecitabine-Related Toxicities in Metastatic Breast Cancer Patients," p. 39, Mon, 9:00 AM – 1:00 PM
	26	Leo S., et al., Journal of Chemotherapy, Vol. 6, n. 6 "Dermatological Toxicity from Chemotherapy Containing 5-Fluorouracil," pp. 2-5, 1994
	27	Levy S., et al. Clinical Therapeutics/Vol. 23, No. 6, "A Pharmacokinetic Evaluation of 0.5% and 5% Fluorouracil Topical Cream in Patients with Actinic Keratosis," pp. 908-920, 2001
	28	Luccioni, et al., Int. J. Cancer: 58, "Pyrimidine Nucleotide Metabolism in Human Colon Carcinomas: Comparison of Normal Tissues Primary Tumors and Xenografts," pp. 32-37, 1994
	29	Mackean M., et al., Journal of Clinical Oncology, Vol. 16, No. 9, "Phase I and Pharmacologic Study of Intermittent Twice-Daily Oral Therapy with Capecitabine in Patients with Advanced and/or Metastatic Cancer," pp. 2977-2985, September, 1998
	30	Maehara Y., et al., Oncology, Vol. 11, No. 9, "Scientific Basis for the Combination of Tegafur with Uracil," pp. 14-21, Supplement No. 10
	31	Malet-Martino M., et al., The Oncologist 2002, "Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review," pp. 288-323
	32	Niedzwicki J., et al., Biochemical Pharmacology, Vol. 32, No. 3, "Structure-Activity Relationship of Ligands of the Pyrimidine Nucleoside Phosphorylases," pp. 399-415, 1983
	33	Niedzwicki J., et al., Biochemical Pharmacology, Vol. 33, No. 15, "Structure-Activity Relationship of Pyrimidine Base Analogs as Ligands of Orotate Phosphoribosyltransferase," pp. 2383-2395, 1984
	34	Naguib, et al., Cancer Research 45, "Enzymes of Uracil Catabolism in Normal and Neoplastic Human Tissues," pp. 5405-5412, November 1985
	35	Spicer E., et al., "Toxicity Study of Uracil in Dogs," pp. 199-204
	36	Senff H., et al., British Journal of Dermatology 118, "Topical 5-Fulorouracil Solution in the Treatment of Warts—Clinical Experience and Percutaneous Absorption," pp. 409-414, 1988
	37	Sawada N., et al., Clinical Cancer Research, Vol. 4, "Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts," pp. 1013-1019, April 1998
	38	Sludden J., et al., Pharmacology, "Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse," pp. 276-280, 1998
	39	Wang J., et al., Anticancer Research 24, "Oral 5-FU is a More Effective Antimetastatic Agent than UFT," pp. 1353-1360 (2004)

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Form PTO-1449	Attorney's Docket No. 41421.0101 CIP1	Application Serial No. 10/684,203
INFORMATION DISCLOSURE STATEMENT	Applicant(s) John P. FORD	
(use several sheets if necessary)	Filing Date: October 10, 2003	Group Art Unit: 1614

OTHER DOCUMENTS
(including author, title, date, pertinent pages, etc.)

	40	Ichikawa W., et al., Gastrointestinal Cancer, "Polymorphisms of orotate phosphoribosyl transferase (OPRT) gene and thymidylate synthase tandem repeat (TSTR) predict adverse events (AE) in colorectal cancer (CRC) patients treated with 5-fluorouracil (FU) pluis leucovorin (LV)," p. 1063, 2003
	41	Schilsky R.L., et al., Food and Drug Administration Center for Drug Evaluation and Research, "Sixty-Third Meeting of the Oncologic Drug Advisory Committee", Sept. 16, 1999
	42	Unknown, Oncology News International, "Lower Dose Capecitabine Is Active and Has Favorable Safety Profile in Elderly Patients With Advanced Breast Cancer," p. 40, August 2003
	43	Unknown, Roche Pharmaceuticals, "Xeloda (capecitabine) Tablets," April 2003
	44	Samid, D., Roche Laboratories Inc., "Important Information About Xeloda (capecitabine) Tablets," August 2003
	45	Hartmann, H.R., et al., Med. Oncol. & Tumor Pharmacother." Vol. 3 No. 2, "Modulation of the Effects of Fluoropyrimidines on Toxicity and Tumor Inhibition in Rodents by Uridine and Thymidine," pp. 111-118, April 25, 1986
	46	
	47	
	48	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	